"Immunization, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
| Descriptor ID |
D007117
|
| MeSH Number(s) |
E02.095.465.425.400.485 E05.478.550.550
|
| Concept/Terms |
Immunization, Secondary- Immunization, Secondary
- Immunizations, Secondary
- Secondary Immunizations
- Immunization, Booster
- Booster Immunization
- Booster Immunizations
- Immunizations, Booster
- Secondary Immunization
|
Below are MeSH descriptors whose meaning is more general than "Immunization, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Immunization, Secondary".
This graph shows the total number of publications written about "Immunization, Secondary" by people in this website by year, and whether "Immunization, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 4 | 4 |
| 2025 | 0 | 3 | 3 |
| 2026 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunization, Secondary" by people in Profiles.
-
Repeat Influenza Vaccination Effects in 2021/22 and 2022/23 in a Community-Based Cohort in Hong Kong. J Infect Dis. 2026 Jun 16; 233(6):e1364-e1373.
-
Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults. Front Immunol. 2026; 17:1779435.
-
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia. J Infect. 2026 Apr; 92(4):106727.
-
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19; 76:128348.
-
Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses. EBioMedicine. 2026 Jan; 123:106087.
-
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
-
Pre-existing immunity modulates responses to mRNA boosters. Cell Rep. 2023 03 28; 42(3):112167.
-
Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India. Med. 2023 03 10; 4(3):182-190.e3.
-
Need for pneumococcal revaccination after blinatumomab therapy: A case report. Pediatr Blood Cancer. 2023 06; 70(6):e30237.